Cargando…

Retrospective Analysis of Bevacizumab in Combination with Ifosfamide, Carboplatin, and Etoposide in Patients with Second Recurrence of Glioblastoma

Bevacizumab has been reported to be effective for recurrent glioblastoma. In our hospital, ifosfamide, carboplatin, etoposide (ICE) is the second-line chemotherapy for first recurrence of glioblastoma after temozolomide failure. In the present analysis, we retrospectively investigated the feasibilit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Arakawa, Yoshiki, Mizowaki, Takashi, Murata, Daiki, Fujimoto, Koichi, Kikuchi, Takayuki, Kunieda, Takeharu, Takahashi, Jun C., Takagi, Yasushi, Miyamoto, Susumu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Japan Neurosurgical Society 2013
Materias:	Special Theme Topic: Treatment of Malignant Brain Tumor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4508722/ https://www.ncbi.nlm.nih.gov/pubmed/24140770 http://dx.doi.org/10.2176/nmc.oa2013-0211

Ejemplares similares

Dendritic Cell-Based Immunotherapy for Glioma: Multiple Regimens and Implications in Clinical Trials
por: Mineharu, Yohei, et al.
Publicado: (2013)

Addition of lenalidomide to rituximab, ifosfamide, carboplatin, etoposide (RICER) in first-relapse/primary refractory diffuse large B-cell lymphoma
por: Feldman, Tatyana, et al.
Publicado: (2014)

New Treatment Strategies to Eradicate Cancer Stem Cells and Niches in Glioblastoma
por: Hide, Takuichiro, et al.
Publicado: (2013)

Mechanisms of Tumor Development and Anti-angiogenic Therapy in Glioblastoma Multiforme
por: Onishi, Manabu, et al.
Publicado: (2013)

Usefulness of FMISO—PET for Glioma Analysis
por: Kobayashi, Hiroyuki, et al.
Publicado: (2013)

Advantages of Dose-Dense Methotrexate Protocol for Primary Central Nervous System Lymphoma: Comparison of Two Different Protocols at a Single Institution
por: Aoki, Hiroshi, et al.
Publicado: (2013)

Treatment Results of Glioblastoma during the Last 30 Years in a Single Institute
por: Kumabe, Toshihiro, et al.
Publicado: (2013)

Carfilzomib combined with rituximab, ifosfamide, carboplatin, and etoposide for relapsed or refractory DLBCL
por: Torka, Pallawi, et al.
Publicado: (2022)

Delayed rhabdomyolysis with paclitaxel, ifosfamide, carboplatin, and etoposide regimen: a case report
por: Sokolova, Alexandra, et al.
Publicado: (2017)

Treatment outcomes of T and natural‐killer/T‐cell lymphoma with ifosfamide, carboplatin and etoposide chemotherapy
por: Tay, Tricia, et al.
Publicado: (2022)

Gliosarcoma with Systemic Metastasis Showing Favorable Response to Ifosfamide, Carboplatin, and Etoposide Chemotherapy: An Autopsy Case Report
por: NAKAGAKI, Yuki, et al.
Publicado: (2022)

Bortezomib, Ifosfamide, Carboplatin, and Etoposide in a Patient with HIV-Negative Relapsed Plasmablastic Lymphoma
por: Akce, Mehmet, et al.
Publicado: (2016)

Comparison of Ifosfamide, Carboplatin and Etoposide versus Etoposide, Steroid, and Cytarabine Cisplatin as Salvage Chemotherapy in Patients with Refractory or Relapsed Hodgkin's lymphoma
por: Mehrzad, Valiollah, et al.
Publicado: (2017)

Impact of dexamethasone, etoposide, ifosfamide and carboplatin as concurrent chemoradiotherapy agents for nasal natural killer/T-cell lymphoma
por: HATAYAMA, YOSHIOMI, et al.
Publicado: (2013)

Carboplatin, ifosfamide and etoposide with mid-course vincristine and thoracic radiotherapy for 'limited' stage small cell carcinoma of the bronchus.
por: Thatcher, N., et al.
Publicado: (1989)

Radiotherapy versus combination radiotherapy-bevacizumab for the treatment of recurrent high-grade glioma: a systematic review
por: Kulinich, Daniel P., et al.
Publicado: (2021)

Ifosfamide, Cisplatin or Carboplatin, and Etoposide (ICE)-based Chemotherapy for Mobilization of Autologous Peripheral Blood Stem Cells in Patients with Lymphomas
por: Zhou, Ping, et al.
Publicado: (2015)

Outcome and toxicity of ifosfamide, carboplatin, and etoposide versus gemcitabine and vinorelbine regimen for pediatric patients with relapsed or refractory Hodgkin’s lymphoma
por: Mahdy, Ahmed, et al.
Publicado: (2023)

Response to ifosfamide, carboplatin, etoposide (ICE) vs. dexamethasone, cytarabine cisplatin (DHAP) as salvage chemotherapy in patients with relapsed/refractory lymphoma
por: Devi, Kanta, et al.
Publicado: (2023)

Impact of imatinib on the pharmacokinetics and in vivo efficacy of etoposide and/or ifosfamide
por: Rezaï, Keyvan, et al.
Publicado: (2007)

Comparison of Nutrition-Related Adverse Events and Clinical Outcomes Between ICE (Ifosfamide, Carboplatin, and Etoposide) and MCEC (Ranimustine, Carboplatin, Etoposide, and Cyclophosphamide) Therapies as Pretreatment for Autologous Peripheral Blood Stem Cell Transplantation in Patients with Malignant Lymphoma
por: Aoyama, Takashi, et al.
Publicado: (2018)

GCT-50. LONG-TERM OUTCOMES OF INTRACRANIAL GERMINOMA IN A SINGLE INSTITUTION
por: Yamamoto, Etsuko, et al.
Publicado: (2020)

Rituximab plus Ifosfamide, Carboplatin and Etoposide for T-Cell/Histiocyte-Rich B-Cell Lymphoma Arising in Nodular Lymphocyte-Predominant Hodgkin's Lymphoma
por: Park, Hyung-Chul, et al.
Publicado: (2012)

Ifosfamide, Carboplatin, and Etoposide (ICE) in Combination with Regional Hyperthermia as Salvage Therapy in Patients with Locally Advanced Nonmetastatic and Metastatic Soft-Tissue Sarcoma
por: Bücklein, Veit, et al.
Publicado: (2020)

Use of ifosfamide, carboplatin and etoposide in combination with brentuximab vedotin or romidepsin based on CD30 positivity in relapsed/refractory peripheral T‐cell lymphoma
por: Gentille, Cesar, et al.
Publicado: (2022)

Locoregional CAR T cells for children with CNS tumors: Clinical procedure and catheter safety
por: Vitanza, Nicholas A., et al.
Publicado: (2023)

Unsupervised machine learning using K-means identifies radiomic subgroups of pediatric low-grade gliomas that correlate with key molecular markers
por: Haldar, Debanjan, et al.
Publicado: (2022)

Interdisciplinary care of children with diffuse midline glioma
por: Coleman, Christina, et al.
Publicado: (2022)

Cerebrospinal Fluid biomarkers in pediatric brain tumors: A systematic review
por: Lehner, Kurt R., et al.
Publicado: (2022)

Current state of pediatric neuro-oncology imaging, challenges and future directions
por: Nabavizadeh, Ali, et al.
Publicado: (2023)

Developing H3K27M mutant selective radiosensitization strategies in diffuse intrinsic pontine glioma
por: Parsels, Leslie A., et al.
Publicado: (2023)

Indigenous peoples and inclusion in clinical and genomic research: Understanding the history and navigating contemporary engagement
por: Waanders, Angela, et al.
Publicado: (2023)

Why haven't we solved intracranial pediatric ependymoma? Current questions and barriers to treatment advances.
por: Hwang, Eugene I., et al.
Publicado: (2023)

The promise of metabolic imaging in diffuse midline glioma
por: Lovibond, Samantha, et al.
Publicado: (2023)

Translational considerations for immunotherapy clinical trials in pediatric neuro-oncology
por: Foster, Jessica B., et al.
Publicado: (2023)

Retrospective dataset and survey analyses identify gaps in data collection for craniopharyngioma and priorities of patients and families affected by the disease
por: Marshall, Emily, et al.
Publicado: (2023)

Phase I study of selinexor in combination with dexamethasone, ifosfamide, carboplatin, etoposide chemotherapy in patients with relapsed or refractory peripheral T-cell or natural-killer/T-cell lymphoma
por: Tang, Tiffany, et al.
Publicado: (2020)

Valsalva-Like Retinopathy Secondary to Pancytopenia following Induction of Etoposide and Ifosfamide
por: Prinzi, Robert A., et al.
Publicado: (2015)

Visualization of heterogeneity and regional grading of gliomas by multiple features using magnetic resonance-based clustered images
por: Inano, Rika, et al.
Publicado: (2016)

Gemcitabine, cisplatin, and dexamethasone and ifosfamide, carboplatin, and etoposide regimens have similar efficacy as salvage treatment for relapsed/refractory aggressive lymphoma: A retrospectively comparative study
por: Mi, Mi, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_gbkhqkm929tcolh0cqlpnmdhg8